GenCRISPR Synthetic sgRNA
Accelerate precision gene editing with GenScript's customized synthetic sgRNA, up to 266 nt in length.
Receive your quote directly from the manufacturer.
Custom synthetic single guide RNA (sgRNA) for gene editing, screening, and diagnostics applications. Compatible with Cas9, Cpf1 (Cas12a), Prime Editing, and more gene editing systems. Bespoke service with customization options and a responsive support team to answer your questions.
Access our intelligent GenCRISPR sgRNA Design Tool to easily design high-performance guide RNA, algorithmically ranked by on-target and off-target scores.
Advanced mRNA and LNP Strategies for CRISPR Delivery
Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.
Recent breakthroughs in RNA therapeutics have unveiled the incredible potential of mRNA-based tools for gene editing. Lipid nanoparticles (LNPs) can co-encapsulate mRNA and guide RNA for highly efficient delivery both to cells in vitro and in vivo.
GenScript’s cutting-edge platform produces top-quality mRNA with enhanced expression, reduced immunogenicity, and extended half-life. Paired with a novel guide RNA design, this guarantees exceptional editing efficiency with low off-target effects.
In this webinar, Dr. Shambhavi Shubham, field application scientist at GenScript will share how the company harnesses advanced formulations of CRISPR enzymes like Cas9 and Cas12, and Prime editing to achieve powerful gene editing. To further elevate performance, GenScript leverages advanced strategies, including customizing CRISPR mRNAs with tissue-specific UTRs, optimizing IVT conditions to reduce dsRNA, and using codon optimization and circular RNA forms. Moreover, to meet precise delivery needs, GenScript technology leverages antibody-decorated or SORT LNPs.
Join us and learn how GenScript’s advanced platform serves the needs of researchers and biopharmaceutical companies by driving the rapid development of ground-breaking therapeutics and propelling genetics research forward.
Key learning objectives
- Understand the mechanisms and potential of mRNA-based tools for gene editing
- Discover the use of lipid nanoparticles (LNPs) for co-encapsulating mRNA and guide RNA, facilitating efficient delivery in vitro and ex vivo
- Gain insights into advanced formulations incorporating CRISPR mRNA like Cas9 and Cas12, as well as prime editing
- Explore strategies for achieving targeted delivery through antibody-decorated LNPs or SORT LNPs to increase efficiency at specific sites
Who should attend?
Audiences working on mRNA, gene editing, and LNP delivery solutions
Interested in this webinar? Explore the other webinars in this series on Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines and Self-Amplifying RNA in Vaccines and Beyond
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes
De-risk your CRISPR pipeline with scalable cGMP guide RNA
Tuesday, April 8, 2025 – 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
Join us for an exclusive webinar with Dr. Pedro Teh as he explores how expert guide RNA (gRNA) manufacturing services can help accelerate your CRISPR-based therapeutic development in line with current good manufacturing practices (cGMP).
As a trusted partner in cell and gene therapy, GenScript provides high-quality, scalable, and regulatory-compliant gRNA for CRISPR systems including Cas9, Cas12a, prime editing, and base editing.
Discover how GenScript's cGMP synthesis capabilities and state-of-the-art production facility ensures a streamlined 30-day turnaround for clinical-grade gRNA, and see how comprehensive documentation support – including Drug Master Files (DMFs) – can facilitate smooth investigational new drug (IND) submissions and regulatory approvals.
Whether you're in early-stage research or preparing for clinical trials, this webinar will show you how GenScript's expertise in cGMP nucleic acid manufacturing, quality control, and regulatory support can help de-risk and accelerate your CRISPR therapeutic pipeline.
Key learning objectives:
- Learn about cGMP guide RNA manufacturing and quality control processes
- Explore a range of gene editing approaches that can be supported by cGMP gRNA services
- Understand how expert documentation support simplifies IND submissions and regulatory approvals
- Learn why procuring RUO to cGMP gRNA from a single vendor streamlines and de-risks the development process for CRISPR therapies
Who should attend?
Scientists and decision-makers from biopharma, biotech, and academic institutions using gene editing for discovery or preclinical research.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines
Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.
This webinar introduces the fundamentals of neoantigen peptide discovery and its importance in personalized cancer immunotherapy. Dr. Shan She, Senior Global Product Manager at GenScript will discuss advances and current trends in neoantigen peptide applications, emphasizing their potential to improve the specificity and effectiveness of cancer vaccines.
This session will also explore GenScript's innovative technologies and one-stop solutions for neoantigen research, offering insights into successful case studies and practical applications. Ideal for researchers in academia and biopharmaceutical companies, this webinar will provide a comprehensive overview of neoantigen peptide research and therapeutic applications.
Join us and gain deep insight into how GenScript's high-quality services support this field.
Key learning objectives
- Learn the history of neoantigen peptides
- Explore neoantigen peptide market research
- Understand neoantigen peptide classification and challenges
- Discover GenScript’s customized service offerings and see how they can support your research
Who should attend?
- Researchers in academia and biopharmaceutical companies
Interested in this webinar? Explore the other webinars in this series on Advanced mRNA and LNP Strategies for CRISPR Delivery and Self-Amplifying RNA in Vaccines and Beyond
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes
Self-Amplifying RNA in Vaccines and Beyond
Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.
The remarkable success of SARS-CoV2 vaccines has brought to light the incredible potential of in vitro transcribed RNA as a ground-breaking vaccine platform. Unlike traditional vaccines, RNA vaccines offer the exciting possibility of swift development and production, enabling rapid responses to emerging diseases. A recent breakthrough in RNA vaccine technology is the development of self-amplifying RNAs, which not only generate higher levels of immunogens but also require lower doses compared with conventional RNA vaccines.
This webinar will delve into the innovative world of self-amplifying RNAs as a cutting-edge RNA modality. Throughout the session, we will explore what self-amplifying RNAs are, how they differ from conventional RNA and their potential impact on shaping the next generation of RNA vaccines and other therapeutic applications.
Join Mark Shulewitz, PhD, senior scientist at GenScript for an enlightening discussion on the future of vaccine technology.
Key learning objectives
- Learn how RNA is used in vaccines and other therapeutic applications such as protein replacement therapy
- Discover what modalities of RNA are currently being explored for therapeutic applications
- Explore the shortcomings of conventional RNA and how self-amplifying RNA addresses some of these issues
- Gain insight into the latest developments in self-amplifying RNAs
Who should attend?
- Experienced RNA users interested in learning more about self-amplifying RNA
- Absolute beginners interested in learning about self-amplifying RNA
- Researchers interested in RNA vaccine development and protein replacement therapies
- Life science, biopharma and pharmaceutical professionals interested in cutting-edge technologies that have multiple applications in therapeutic development and basic life science research
- Developers of traditional vaccines looking for a new approach
Interested in this webinar? Explore the other webinars in this series on Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines and Advanced mRNA and LNP Strategies for CRISPR Delivery
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes
